In contrast to somatostatin analogue withdrawal in acromegaly patients [8], currently there is no agreed consensus for how long in advance DA should be suspended prior to Met-PET/MRICR, but based on the half-life of cabergoline, the dose, and its biological effects, a period of 4 weeks is recommended, which can be extended if there is insufficient elevation of prolactin. Here, PRL is linked to acromegaly.